FDA Approved: BYLVAY — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)

View source ↗

Summary

The document notes a supplemental application submission for BYLVAY (odevixibat) by Ipsen Biopharmaceuticals, Inc., related to labeling changes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Familial Intrahepatic Cholestasis

Drugs mentioned

• BYLVAY (odevixibat)

Snippet

SUPPL AP for BYLVAY (ODEVIXIBAT)